Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $4,730,136.75 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director G. Walmsley Graham sold 700,761 shares of the firm’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $6.75, for a total value of $4,730,136.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA opened at $5.79 on Friday. Olema Pharmaceuticals, Inc. has a fifty-two week low of $5.56 and a fifty-two week high of $16.77. The stock has a market cap of $331.76 million, a PE ratio of -2.64 and a beta of 1.92. The firm’s fifty day moving average price is $10.28 and its two-hundred day moving average price is $11.76.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of Olema Pharmaceuticals by 105.0% during the third quarter. Barclays PLC now owns 94,915 shares of the company’s stock worth $1,133,000 after purchasing an additional 48,614 shares during the period. Conway Capital Management Inc. bought a new stake in Olema Pharmaceuticals during the third quarter valued at $119,000. XTX Topco Ltd boosted its position in shares of Olema Pharmaceuticals by 103.4% during the 3rd quarter. XTX Topco Ltd now owns 25,332 shares of the company’s stock valued at $302,000 after purchasing an additional 12,878 shares in the last quarter. EP Wealth Advisors LLC grew its stake in Olema Pharmaceuticals by 5.2% during the third quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock worth $581,000 after purchasing an additional 2,407 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Olema Pharmaceuticals by 10.8% in the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after purchasing an additional 97,428 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, December 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Olema Pharmaceuticals has an average rating of “Buy” and a consensus target price of $27.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.